Cancer center spins off diagnostic company
The Barbara Ann Karmanos Cancer Institute has launched a new company to build and market a breast cancer screening device invented at the institute, one that uses ultrasound and computer algorithms to assess patients.
The Barbara Ann Karmanos Cancer Institute has launched a new company to build and market a breast cancer screening device invented at the institute, one that uses ultrasound and computer algorithms to assess patients. The spin-off company, called Delphinus Medical Technologies, is dedicated to developing SoftVue as a commercial product. Clinical research has been conducted under an investigational device exemption from the FDA. The company is currently pursuing FDA approval to sell products based on the technology in the U.S. More than 300 women have been studied in initial clinical trials, which the company says has confirmed SoftVue as safe and accurate in identifying breast cancer.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
